HRTX · Heron Therapeutics, Inc. · Analyst Estimates
$0.27
+0.01 (+2.23%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If the payment of the debt is accelerated, absent any additional funding, cash flows from our operations will be insufficient to repay such debt in full. Therefore, if all outstanding amounts under the Working Capital Facility Agreement are accelerated, management expects there will be substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 9, 2026
Market Cap
$50.25M
Shares
190.27M
Volume · Nov 19
3.61M
Avg daily vol (3M)
4.54M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Heron Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-16 21:41 UTC · Publication dates shown per estimate · 7 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.15
|
-0.14
|
-0.12
|
2
|
-0.13
|
-0.13
|
-0.13
|
-0.13
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
139.10M
|
141.60M
|
144.10M
|
2
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.14
|
-0.12
|
-0.10
|
2
|
-0.11
|
-0.11
|
-0.11
|
-0.11
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
140.40M
|
140.40M
|
140.40M
|
1
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.03
|
-0.025
|
-0.02
|
2
|
-0.02
|
-0.02
|
-0.02
|
-0.02
|
1
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
31.50M
|
34.00M
|
36.50M
|
2
|
— | — | — | — | — | — | — | — |
Q ending 2027-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
— | — | — | — | — | — | — | — |
Key facts
CIK
818033
CUSIP
427746102
13F (30d)
157 filings
141 filers
Visit website
Investor relations